Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.28
BRLI's Cash to Debt is ranked lower than
51% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.63 vs. BRLI: 0.28 )
BRLI' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 0.28

Equity to Asset 0.64
BRLI's Equity to Asset is ranked higher than
65% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.68 vs. BRLI: 0.64 )
BRLI' s 10-Year Equity to Asset Range
Min: 0.33   Max: 0.73
Current: 0.64

0.33
0.73
Interest Coverage 51.04
BRLI's Interest Coverage is ranked higher than
61% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 138.50 vs. BRLI: 51.04 )
BRLI' s 10-Year Interest Coverage Range
Min: 0.85   Max: 52.32
Current: 51.04

0.85
52.32
F-Score: 5
Z-Score: 6.52
M-Score: -1.91
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 11.46
BRLI's Operating margin (%) is ranked higher than
84% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.31 vs. BRLI: 11.46 )
BRLI' s 10-Year Operating margin (%) Range
Min: -6.49   Max: 12.39
Current: 11.46

-6.49
12.39
Net-margin (%) 6.41
BRLI's Net-margin (%) is ranked higher than
80% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.95 vs. BRLI: 6.41 )
BRLI' s 10-Year Net-margin (%) Range
Min: -9.28   Max: 8.27
Current: 6.41

-9.28
8.27
ROE (%) 16.87
BRLI's ROE (%) is ranked higher than
91% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.30 vs. BRLI: 16.87 )
BRLI' s 10-Year ROE (%) Range
Min: -43.48   Max: 21.83
Current: 16.87

-43.48
21.83
ROA (%) 10.87
BRLI's ROA (%) is ranked higher than
91% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.07 vs. BRLI: 10.87 )
BRLI' s 10-Year ROA (%) Range
Min: -15.48   Max: 13.48
Current: 10.87

-15.48
13.48
ROC (Joel Greenblatt) (%) 34.07
BRLI's ROC (Joel Greenblatt) (%) is ranked higher than
83% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.52 vs. BRLI: 34.07 )
BRLI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -25.55   Max: 41.98
Current: 34.07

-25.55
41.98
Revenue Growth (%) 16.30
BRLI's Revenue Growth (%) is ranked higher than
92% of the 134 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.90 vs. BRLI: 16.30 )
BRLI' s 10-Year Revenue Growth (%) Range
Min: 1.3   Max: 22.4
Current: 16.3

1.3
22.4
EBITDA Growth (%) 19.60
BRLI's EBITDA Growth (%) is ranked higher than
89% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.00 vs. BRLI: 19.60 )
BRLI' s 10-Year EBITDA Growth (%) Range
Min: -18.1   Max: 37.3
Current: 19.6

-18.1
37.3
EPS Growth (%) 20.60
BRLI's EPS Growth (%) is ranked higher than
89% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.30 vs. BRLI: 20.60 )
BRLI' s 10-Year EPS Growth (%) Range
Min: -61.8   Max: 196.2
Current: 20.6

-61.8
196.2
» BRLI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

BRLI Guru Trades in Q1 2013

John Hussman 116,000 sh (New)
Chase Coleman 220,000 sh (New)
Paul Tudor Jones 30,600 sh (+93.67%)
Joel Greenblatt 104,240 sh (+21.81%)
Jean-Marie Eveillard 12,000 sh (unchged)
Mario Gabelli 46,800 sh (-2.09%)
Jim Simons 108,104 sh (-59.78%)
» More
Q2 2013

BRLI Guru Trades in Q2 2013

Chuck Royce 178,000 sh (New)
Chase Coleman 720,000 sh (+227.27%)
Mario Gabelli 54,200 sh (+15.81%)
John Hussman 116,000 sh (unchged)
Jean-Marie Eveillard 12,000 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones 18,000 sh (-41.18%)
Joel Greenblatt 56,271 sh (-46.02%)
» More
Q3 2013

BRLI Guru Trades in Q3 2013

Paul Tudor Jones 18,900 sh (+5%)
Mario Gabelli 55,700 sh (+2.77%)
Jean-Marie Eveillard 12,000 sh (unchged)
Chase Coleman 720,000 sh (unchged)
John Hussman Sold Out
Joel Greenblatt 47,324 sh (-15.9%)
Chuck Royce 115,600 sh (-35.06%)
» More
Q4 2013

BRLI Guru Trades in Q4 2013

Paul Tudor Jones 31,198 sh (+65.07%)
Mario Gabelli 56,400 sh (+1.26%)
Jean-Marie Eveillard 12,000 sh (unchged)
Chuck Royce 115,600 sh (unchged)
Chase Coleman 720,000 sh (unchged)
Joel Greenblatt 30,507 sh (-35.54%)
» More
» Details

Insider Trades

Latest Guru Trades with BRLI

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-12-31 Reduce -35.54%0.02%$25.17 - $37.73 $ 27.23-12%30507
John Hussman 2013-09-30 Sold Out 0.15%$25.78 - $30.14 $ 27.23-2%0
Joel Greenblatt 2013-06-30 Reduce -46.02%0.06%$23.58 - $31.9 $ 27.23-1%56271
John Hussman 2013-03-31 New Buy0.11%$24.91 - $31.05 $ 27.23-2%116000
Joel Greenblatt 2013-03-31 Add 21.81%0.03%$24.91 - $31.05 $ 27.23-2%104240
Joel Greenblatt 2012-12-31 Add 48.67%0.05%$24.68 - $32.42 $ 27.23-5%85579
Joel Greenblatt 2012-03-31 New Buy0.12%$16.27 - $23.76 $ 27.2345%57406
Mario Gabelli 2011-06-30 Add 27.78%$20.57 - $25.24 $ 27.2317%36800
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Bio-Reference Laboratories Inc

Medical Diagnostic Labs Facing Medicare Headwinds
Currently medical diagnostic lab stocks are trading at near historical lows for price-to-sales (P/S). At first sight these companies might look like bargains, but lower p/s ratios might be the new normal for these companies. I have taken a closer look at Lab Corp of America (LH), Quest Diagnostics (DGX), and Bio-Reference Labs (BRLI). Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 18.70
BRLI's P/E(ttm) is ranked higher than
73% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.50 vs. BRLI: 18.70 )
BRLI' s 10-Year P/E(ttm) Range
Min: 9.34   Max: 39.85
Current: 18.7

9.34
39.85
P/B 2.80
BRLI's P/B is ranked higher than
66% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. BRLI: 2.80 )
BRLI' s 10-Year P/B Range
Min: 1.77   Max: 7.83
Current: 2.8

1.77
7.83
P/S 1.00
BRLI's P/S is ranked higher than
86% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.63 vs. BRLI: 1.00 )
BRLI' s 10-Year P/S Range
Min: 0.58   Max: 2.44
Current: 1

0.58
2.44
EV-to-EBIT 10.90
BRLI's EV-to-EBIT is ranked higher than
82% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.08 vs. BRLI: 10.90 )
BRLI' s 10-Year EV-to-EBIT Range
Min: 5.9   Max: 28.6
Current: 10.9

5.9
28.6
PEG 0.90
BRLI's PEG is ranked higher than
88% of the 52 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. BRLI: 0.90 )
BRLI' s 10-Year PEG Range
Min: 0.36   Max: 1.24
Current: 0.9

0.36
1.24
Shiller P/E 22.90
BRLI's Shiller P/E is ranked higher than
81% of the 52 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.50 vs. BRLI: 22.90 )
BRLI' s 10-Year Shiller P/E Range
Min: 15.23   Max: 270
Current: 22.9

15.23
270

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 20.90
BRLI's Price/Net Current Asset Value is ranked lower than
73% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.40 vs. BRLI: 20.90 )
BRLI' s 10-Year Price/Net Current Asset Value Range
Min: 11.78   Max: 71.72
Current: 20.9

11.78
71.72
Price/Tangible Book 3.40
BRLI's Price/Tangible Book is ranked higher than
71% of the 136 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. BRLI: 3.40 )
BRLI' s 10-Year Price/Tangible Book Range
Min: 0.68   Max: 9
Current: 3.4

0.68
9
Price/DCF (Projected) 2.00
BRLI's Price/DCF (Projected) is ranked higher than
54% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.70 vs. BRLI: 2.00 )
BRLI' s 10-Year Price/DCF (Projected) Range
Min: 1.76   Max: 46.69
Current: 2

1.76
46.69
Price/Median PS Value 0.80
BRLI's Price/Median PS Value is ranked higher than
84% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. BRLI: 0.80 )
BRLI' s 10-Year Price/Median PS Value Range
Min: 0.11   Max: 1.75
Current: 0.8

0.11
1.75
Price/Peter Lynch Fair Value 0.90
BRLI's Price/Peter Lynch Fair Value is ranked higher than
92% of the 36 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. BRLI: 0.90 )
BRLI' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.61   Max: 4.39
Current: 0.9

0.61
4.39
Price/Graham Number 1.70
BRLI's Price/Graham Number is ranked higher than
71% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. BRLI: 1.70 )
BRLI' s 10-Year Price/Graham Number Range
Min: 0.3   Max: 5.26
Current: 1.7

0.3
5.26
Earnings Yield (Greenblatt) 9.20
BRLI's Earnings Yield (Greenblatt) is ranked higher than
80% of the 120 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.70 vs. BRLI: 9.20 )
BRLI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.5   Max: 16.9
Current: 9.2

3.5
16.9
Forward Rate of Return (Yacktman) 22.63
BRLI's Forward Rate of Return (Yacktman) is ranked higher than
95% of the 138 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.42 vs. BRLI: 22.63 )
BRLI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -5.5   Max: 34.5
Current: 22.63

-5.5
34.5

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, DGX, LIFE, ENZ, IDXX » details
Traded in other countries:BFR.Germany
Bio-Reference Laboratories, Inc., is a New Jersey corporation incorporated on December 24, 1981. It offers testing, information and related services to physician offices, clinics, hospitals, employers and governmental units. It offers a comprehensive list of laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring and treatment of diseases. It mainly focuses on esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional health care. The Company currently process approximately 6.7 million laboratory test requisitions each year. It has a network of 98 patient service centers located in the Northeast (mainly in New York metropolitan super-regional area) for collection of patient specimens. It currently conducts business in most New York State counties, as well as in most of New Jersey and Maryland as well as some parts of Pennsylvania, Delaware and Connecticut. It mainly offers laboratory services to physician offices in these areas with an infrastructure that includes a comprehensive logistical department, extensive phlebotomy services and phlebotomy draw stations scattered around its geographic area. The Company also operates a web-based connectivity portal solution for laboratories and physicians through its CareEvolve subsidiary. It uses this portal itself to provide laboratory ordering and results as well as connectivity to its physician customers. It also markets and licenses this connectivity solution to other laboratories throughout the country. The Company competes with three types of providers in a highly fragmented and competitive industry: hospital laboratories, physician-office laboratories and other independent clinical laboratories. Its major competitors in the New York metropolitan area are Quest Diagnostics and Laboratory Corporation of America. The Company is subject to federal and state laws and regulations regarding the protection of the environment, the health and safety of employees, and the handling, transportation and disposal of medical specimens, and infectious and hazardous wastes.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide